Boosting CAR t cells: could a pill make lymphoma therapy more effective?
NCT ID NCT05934838
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial explores whether adding the drug tazemetostat (Tazverik) to standard CAR T cell therapy can help the immune cells better recognize and destroy lymphoma cells. It enrolls people with diffuse large B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma who have already tried at least one prior treatment. Participants take tazemetostat pills before and after receiving their CAR T cells, continuing for up to a year, and are monitored for side effects and response for up to five years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tazemetostat (Tazverik) plus CAR T cells
- What this could lead to
- If successful, this combination could make CAR T therapy more effective at killing lymphoma cells, potentially improving long-term control of the disease.
- What could go wrong
- This is a small, early-phase feasibility study, so results may not apply broadly. Adding tazemetostat could increase side effects like cytokine release syndrome or immune-related neurotoxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Weill Cornell Medicine/NewYork-Presbyterian Hospital
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a targeted pill boost Chemotherapy's punch against lymphoma?